MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. Financials Mabwell (Shanghai) Bioscience Co., Ltd.
Equities
688062
CNE100005RD2
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 34.9 CNY | -2.79% |
|
-1.33% | +6.76% |
| May. 07 | Mabwell Announces FDA Grants Orphan Drug Designation to 9MW2821 | CI |
| Apr. 29 | Mabwell Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 5,774 | 13,063 | 13,946 | - | - |
| Enterprise Value (EV) 1 | 5,774 | 13,063 | 13,946 | 13,946 | 13,946 |
| P/E ratio | -5.92 x | -12.4 x | -16.2 x | -23.5 x | -110 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | 102 x | 36.3 x | 12.6 x | 7.2 x |
| EV / Revenue | - | 102 x | 36.3 x | 12.6 x | 7.2 x |
| EV / EBITDA | - | -13.4 x | -18.6 x | -30.8 x | 13,946 x |
| EV / FCF | - | -10.2 x | -13.9 x | -22.4 x | -385 x |
| FCF Yield | - | -9.82% | -7.19% | -4.46% | -0.26% |
| Price to Book | - | 5.05 x | 8.2 x | 12.6 x | 15 x |
| Nbr of stocks (in thousands) | 399,600 | 399,600 | 399,600 | - | - |
| Reference price 2 | 14.45 | 32.69 | 34.90 | 34.90 | 34.90 |
| Announcement Date | 2/20/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 127.7 | 384.5 | 1,106 | 1,937 |
| EBITDA 1 | - | -973 | -750.9 | -452.7 | 1 |
| EBIT 1 | - | -1,053 | -907.5 | -621.1 | -169.7 |
| Operating Margin | - | -824.53% | -236.02% | -56.18% | -8.76% |
| Earnings before Tax (EBT) 1 | - | -1,056 | -864.1 | -595.3 | -126.7 |
| Net income 1 | -954 | -1,053 | -861.9 | -593.7 | -126.3 |
| Net margin | - | -824.94% | -224.15% | -53.71% | -6.52% |
| EPS 2 | -2.440 | -2.640 | -2.156 | -1.486 | -0.3167 |
| Free Cash Flow 1 | - | -1,283 | -1,003 | -622.5 | -36.24 |
| FCF margin | - | -1,004.52% | -260.85% | -56.31% | -1.87% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - |
| Announcement Date | 2/20/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -1,283 | -1,003 | -622 | -36.2 |
| ROE (net income / shareholders' equity) | - | -34.5% | -51.3% | -56.6% | -13.8% |
| ROA (Net income/ Total Assets) | - | -23.6% | -25.3% | -16.5% | -5.2% |
| Assets 1 | - | 4,464 | 3,413 | 3,609 | 2,429 |
| Book Value Per Share 2 | - | 6.470 | 4.250 | 2.770 | 2.330 |
| Cash Flow per Share 2 | - | -1.960 | -3.060 | -0.4800 | -0.2600 |
| Capex 1 | - | 500 | 178 | 128 | 57.5 |
| Capex / Sales | - | 391.51% | 46.16% | 11.53% | 2.97% |
| Announcement Date | 2/20/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
34.9
CNY
Average target price
35.92
CNY
Spread / Average Target
+2.91%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +6.76% | 1.93B | |
| +2.93% | 108B | |
| -2.24% | 23.46B | |
| -14.60% | 21.72B | |
| -7.05% | 18.64B | |
| -38.55% | 17.45B | |
| -8.83% | 17.19B | |
| +5.51% | 13.99B | |
| +37.49% | 12.53B | |
| +329.39% | 8.81B |
- Stock Market
- Equities
- 688062 Stock
- Financials Mabwell (Shanghai) Bioscience Co., Ltd.